No Data
No Data
Investors Don't See Light At End Of Spruce Biosciences, Inc.'s (NASDAQ:SPRB) Tunnel And Push Stock Down 26%
To the annoyance of some shareholders, Spruce Biosciences, Inc. (NASDAQ:SPRB) shares are down a considerable 26% in the last month, which continues a horrid run for the company. The recent drop com
Express News | Spruce Biosciences: Under Asset Purchase Agreement, Co to Acquire Transferred Assets From Eiger for $10.0 Mln Subject to Certain Circumstances
Express News | Spruce Biosciences : On June 17, an Auction Was Conducted With Respect to Transferred Assets as Part of Eiger's Court-Supervised Sale Process
Express News | Spruce Biosciences- Agreed to Buy All Rights,Title,Interests in,to & Under Some Assets,Interests Used by Eiger BioPharmaceuticals Related to Avexitide
Express News | Spruce Biosciences Inc: On June 13, Co Entered Into a "Stalking Horse" Asset Purchase Agreement
Oppenheimer Maintains Spruce Biosciences(SPRB.US) With Buy Rating, Cuts Target Price to $3
Oppenheimer analyst Hartaj Singh maintains $Spruce Biosciences(SPRB.US)$ with a buy rating, and adjusts the target price from $4 to $3.According to TipRanks data, the analyst has a success rate of 43.